| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lisa R Fodero, Javier Sáez-Valero, Catriona A McLean, Ralph N Martins, Konrad Beyreuther, Colin L Masters, Terry A Robertson, David H Smal. Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. Journal of neurochemistry. vol 81. issue 3. 2002-07-05. PMID:12065653. |
previous studies have shown that a minor glycoform of acetylcholinesterase (ache) is increased in alzheimer's disease brain and cerebrospinal fluid. |
2002-07-05 |
2023-08-12 |
mouse |
| Lei Yang, Heng-Yi He, Xue-Jun Zhan. Increased expression of intranuclear AChE involved in apoptosis of SK-N-SH cells. Neuroscience research. vol 42. issue 4. 2002-06-25. PMID:11985878. |
acetylcholinesterase (ache) was suggested to be neurotoxic in vivo and in vitro and accelerate assembly of amyloid peptide into alzheimer's fibrils. |
2002-06-25 |
2023-08-12 |
Not clear |
| Cássio M C Bottino, Isabel A M Carvalho, Ana Maria M A Alvarez, Renata Avila, Patrícia R Zukauskas, Sonia E Z Bustamante, Flávia C Andrade, Sérgio R Hototian, Fabiana Saffi, Cândida H P Camarg. [Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report]. Arquivos de neuro-psiquiatria. vol 60. issue 1. 2002-05-23. PMID:11965412. |
this study aims to show preliminary results of the 'combined treatment' (acetylcholinesterase inhibitor + cognitive training) on a group of mild alzheimer's disease (ad) patients, followed-up for 7 months. |
2002-05-23 |
2023-08-12 |
Not clear |
| H Muck. TAK-147 (Takeda). Current opinion in investigational drugs (London, England : 2000). vol 2. issue 11. 2002-05-07. PMID:11763163. |
tak-147 is a cns-specific acetylcholinesterase inhibitor under development by takeda as a potential treatment for alzheimer's disease. |
2002-05-07 |
2023-08-12 |
Not clear |
| C Carnero Pard. [Are the new drugs for treatment of Alzheimer's disease useful?]. Revista de neurologia. vol 32. issue 2. 2002-05-03. PMID:11299483. |
in recent years several acetylcholinesterase inhibitor drugs have been developed for the treatment of alzheimer s disease. |
2002-05-03 |
2023-08-12 |
Not clear |
| P Bar-On, C B Millard, M Harel, H Dvir, A Enz, J L Sussman, I Silma. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry. vol 41. issue 11. 2002-04-19. PMID:11888271. |
rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of alzheimer's disease under the trade name of exelon. |
2002-04-19 |
2023-08-12 |
human |
| V E Pearso. Galantamine: a new alzheimer drug with a past life. The Annals of pharmacotherapy. vol 35. issue 11. 2002-04-08. PMID:11724094. |
to review the historic, pharmacologic, pharmacokinetic, therapeutic, and toxicologic features of galantamine, a new acetylcholinesterase inhibitor, and to assess its role in the treatment of alzheimer disease symptoms. |
2002-04-08 |
2023-08-12 |
Not clear |
| F Coelho, J Birk. Physostigmine for Alzheimer's disease. The Cochrane database of systematic reviews. issue 2. 2002-02-28. PMID:11405996. |
the main pharmacological approach for the treatment of alzheimer's disease (ad) has been based on the use of agents potentiating cholinergic transmission, particularly by inhibiting acetylcholinesterase (ache), the enzyme that destroys acetylcholine after it has been secreted into the synaptic clefts. |
2002-02-28 |
2023-08-12 |
Not clear |
| R E Mrak, W S Griffi. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiology of aging. vol 22. issue 6. 2002-02-28. PMID:11754997. |
il-1 is overexpressed in alzheimer brain, and this overexpression is directly related to plaque formation and progression, nonsensical growth of dystrophic neurites, and neuronal overexpression of acetylcholinesterase. |
2002-02-28 |
2023-08-12 |
Not clear |
| Xiao Qiu Xiao, Hai Yan Zhang, Xi Can Tan. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. Journal of neuroscience research. vol 67. issue 1. 2002-02-21. PMID:11754078. |
huperzine a, a novel lycopodium alkaloid originally discovered in the chinese herb qian ceng ta (huperzia serrata), is a reversible, potent, and selective acetylcholinesterase (ache) inhibitor and has been extensively used for the treatment of alzheimer's disease (ad) in china. |
2002-02-21 |
2023-08-12 |
rat |
| S Lovestone, D Murra. Acetylcholinesterase treatment--modelling potential demand and auditing practice. International journal of geriatric psychiatry. vol 16. issue 12. 2002-02-11. PMID:11748772. |
acetylcholinesterase inhibitors represent an entirely novel treatment option for patients with alzheimer's disease (ad). |
2002-02-11 |
2023-08-12 |
Not clear |
| T Parnowsk. [The use of acetylcholinesterase inhibitors in Alzheimer's disease]. Przeglad lekarski. vol 58 Suppl 3. 2002-01-29. PMID:11603170. |
[the use of acetylcholinesterase inhibitors in alzheimer's disease]. |
2002-01-29 |
2023-08-12 |
Not clear |
| P Cra. Recent developments in Alzheimer's disease. Acta clinica Belgica. vol 56. issue 5. 2002-01-24. PMID:11770221. |
acetylcholine is deficient in alzheimer's disease and can be supplemented in part by treatment with acetylcholinesterase inhibitors. |
2002-01-24 |
2023-08-12 |
mouse |
| Horacio Pappa, Romina Farrú, Paula Otaño Vilanova, Marcelo Palacios, María Teresa Pizzorn. A new HPLC method to determine Donepezil hydrochloride in tablets. Journal of pharmaceutical and biomedical analysis. vol 27. issue 1-2. 2002-01-17. PMID:11682224. |
donepezil hydrochloride is a reversible inhibitor of acetylcholinesterase, indicated for the treatment of mild to moderate dementia of the alzheimer's type. |
2002-01-17 |
2023-08-12 |
Not clear |
| G B Frison. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. Journal of neurology. vol 248. issue 7. 2002-01-11. PMID:11517995. |
treatment of alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. |
2002-01-11 |
2023-08-12 |
Not clear |
| G B Frison. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. Journal of neurology. vol 248. issue 7. 2002-01-11. PMID:11517995. |
views on drug therapy with acetylcholinesterase inhibitors of the cognitive symptoms of alzheimer's disease are not uniform, varying from excitement at the possibility of significantly improving the personal and social burden of the disease to skeptical and nihilistic attitudes. |
2002-01-11 |
2023-08-12 |
Not clear |
| F I Braginskaya, M Zorina, N P Pal'mina, V D Gaintseva, E B Burlakova, N D Selezneva, I V Kolykhalov, S I Gavrilov. Some blood biochemistry parameters during the cholinergic treatment of Alzheimer's disease. Neuroscience and behavioral physiology. vol 31. issue 4. 2002-01-09. PMID:11508499. |
acetylcholinesterase (ace) activity and lipid peroxidation (lpo) parameters were measured in the blood of patients with alzheimer's disease (ad) during treatment with amiridine and gliatiline. |
2002-01-09 |
2023-08-12 |
Not clear |
| V N Tales. Acetylcholinesterase in Alzheimer's disease. Mechanisms of ageing and development. vol 122. issue 16. 2001-12-31. PMID:11589914. |
acetylcholinesterase in alzheimer's disease. |
2001-12-31 |
2023-08-12 |
Not clear |
| V N Tales. Acetylcholinesterase in Alzheimer's disease. Mechanisms of ageing and development. vol 122. issue 16. 2001-12-31. PMID:11589914. |
since the discovery of the cholinergic deficit in alzheimer disease (ad), acetylcholinesterase (ache) has been widely investigated in tissues involved in the disease. |
2001-12-31 |
2023-08-12 |
Not clear |
| S Amici, A Lanari, R Romani, C Antognelli, V Gallai, L Parnett. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Mechanisms of ageing and development. vol 122. issue 16. 2001-12-31. PMID:11589922. |
at present acetylcholinesterase (ache) inhibitors (acheis) represent the only reliable therapeutic resource for symptomatic treatment of alzheimer disease (ad). |
2001-12-31 |
2023-08-12 |
Not clear |